Baseline factors predicting change from the initial DMARD treatment during the first 2 years of rheumatoid arthritis: experience in the ERAN inception cohort-Reference-Cited by-同舟云学术

Baseline factors predicting change from the initial DMARD treatment during the first 2 years of rheumatoid arthritis: experience in the ERAN inception cohort

Published:2013-05-01 Issue:1 Volume:14 Page:
ISSN:1471-2474
Container-title:BMC Musculoskeletal Disorders
language:en
Short-container-title:BMC Musculoskelet Disord

Author:

McWilliams Daniel F,Kiely Patrick D W,Young Adam,Walsh David A

Publisher

Springer Science and Business Media LLC

Subject

Orthopedics and Sports Medicine,Rheumatology

Link

http://link.springer.com/content/pdf/10.1186/1471-2474-14-153.pdf

Reference29 articles.

1. Pincus T, Marcum SB, Callahan LF: Longterm drug therapy for rheumatoid arthritis in seven rheumatology private practices: II. Second line drugs and prednisone. J Rheumatol. 1992, 19 (12): 1885-1894.

2. Wolfe F: The epidemiology of drug treatment failure in rheumatoid arthritis. Baillieres Clin Rheumatol. 1995, 9 (4): 619-632. 10.1016/S0950-3579(05)80305-X.

3. Schipper LG, Fransen J, den Broeder AA, Van Riel PL: Time to achieve remission determines time to be in remission. Arthritis Res Ther. 2010, 12 (3): R97-10.1186/ar3027.

4. Montag K, Gingold M, Boers A, Littlejohn G: Disease-modifying anti-rheumatic drug usage, prescribing patterns and disease activity in rheumatoid arthritis patients in community-based practice. Intern Med J. 2011, 41 (6): 450-455. 10.1111/j.1445-5994.2010.02240.x.

5. Kiely P, Williams R, Walsh D, Young A: Contemporary patterns of care and disease activity outcome in early rheumatoid arthritis: the ERAN cohort. Rheumatology (Oxford). 2009, 48 (1): 57-60.

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Clinical prediction models for methotrexate treatment outcomes in patients with rheumatoid arthritis: A systematic review and meta-analysis;Seminars in Arthritis and Rheumatism;2022-10

2. Secular changes in functional disability, pain, fatigue and mental well-being in early rheumatoid arthritis. A longitudinal meta-analysis;Seminars in Arthritis and Rheumatism;2020-04

3. High burden of adverse events is associated with reduced remission rates in early rheumatoid arthritis;Clinical Rheumatology;2017-12-26

4. A Multi‐Biomarker Disease Activity Score and the Choice of Second‐Line Therapy in Early Rheumatoid Arthritis After Methotrexate Failure;Arthritis & Rheumatology;2017-03-31

5. Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for the treatment of rheumatoid arthritis not previously treated with disease-modifying antirheumatic drugs and after the failure of conventional disease-modifying antirheumatic drugs only: systematic review and economic evaluation;Health Technology Assessment;2016-04